Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Step by step instructions to Open a Lovely Waterway Voyage Insight: Conveniences, Administrations, and Elite Offers - 2Step by step instructions to Guarantee Your Lab Precious stone is Morally Obtained
- 39 African migrants died in freezing temperatures near Morocco-Algeria border
- 4German gas price bill signed into law, but consumers not impressed
- 5Washington resident contracts bird flu, first human case in U.S. since February
- Find the Interesting Universe of Computerized reasoning: the Capability of man-made intelligence
- Mom finds out she has cancer after noticing something was off while breastfeeding
- Dinosaur collagen used to create one-of-a-kind handbag
- AstraZeneca to invest $2 billion as part of US manufacturing push
- Investigating Inside Plan and Home Style: Change Your Residing Space
- How mountain terraces have helped Indigenous peoples live with climate uncertainty
- Instructions to Distinguish the Wellbeing Dangers Related with 5G Pinnacles
- The Fate of Rest: Patterns in Shrewd Beds
- NASA launches science balloon in Antarctica | Space photo of the day for Dec. 22, 2025
